Pregnancy and Breast-feedingDue to the negligible systemic exposure and the lack of pharmacological activity Celluvisc can be used during pregnancy and breast-feeding.
Eye disorders:Common: Eye irritation (including burning and discomfort), eye pain, eye pruritus, visual disturbance.Postmarketing ExperienceThe following additional adverse reactions have been identified during postmarketing use of Celluvisc in clinical practice. Because postmarketing reporting of these reactions is voluntary and from a population of uncertain size, it is not always possible to reliably estimate the frequency of these reactions.
Immune System Disorders:Hypersensitivity including eye allergy.
Eye Disorders:Blurred vision, eye discharge, lacrimation increased, ocular hyperemia.
Injury, Poisons and Procedural Complications:Superficial injury of eye (from the vial tip touching the eye during administration) and/or corneal abrasion.
Reporting of suspected adverse reactionsReporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via Yellow Card Scheme